Cardiac Biomarkers in Patients with Isolated and Combined Course of Chronic Obstructive Pulmonary Disease and Chronic Heart Failure

The aim of the study was to define cardiac biomarkers in patients with isolated and combined chronic obstructive pulmonary disease (COPD) and chronic heart failure (CHF), to assess their level and diagnostic value in order to optimize the tactics of managing these patients.

Materials and Methods. The study included 184 patients aged 38–85 years who were divided into 3 comparison groups: group 1 (n=68) was composed of patients with I–III stage COPD (GOLD, 2017); group 2 (n=64) patients with I–III functional class CHF; group 3 (n=52) patients with a combined course of COPD and CHF. Specific cardiac biomarkers were evaluated in 80 patients (in group 1 in 26, in group 2 in 27, and in group 3 in 27 patients). Patients’ blood serum obtained by centrifuging was used for cardiac biomarker investigations.

Results. NT-proBNP (F=0.59; p=0.0490) was found to be the most sensitive biomarker for determining the severity degree of the heart damage in the combined course of COPD and CHF. ST2 biomarker reliably reflects the severity of the isolated CHF (F=0.76; p=0.0285), while in the combined course of COPD and CHF, the value of this marker decreases (F=0.76; p=0.4718).

A direct correlation has been established between the level of cardiac biomarker NT-proBNP and CHF functional class both in the isolated and combined course of COPD and CHF.

In patients highly adherent to therapy, statistically significant reduction in the values of ST2 (F=3.22; p=0.0453) and NT-proBNP (F=12.20; p=0.0000) is observed which enables the physicians to control patient adherence to the administered therapy.

The levels of biomarkers have been established at which a high risk of COPD progressing to one step or higher and/or CHF to one functional class and higher is noted in comorbid COPD and CHF course.

Conclusion. The obtained data about the diagnostic value of cardiac biomarkers in comorbid course of COPD and CHF is reasonable to use for therapy optimization in order to improve the quality of patient’s life and decrease the risk of unfavorable outcomes.

1. Global strategy for the diagnosis, management and prevention of COPD. Global initiative for chronic obstructive lung disease (GOLD) 2017. URL: https://goldcopd.org.
2. Vizel’ A.A., Vizel’ I.Yu. Chronic obstructive pulmonary disease: status of the problem in 2016. Lechashchiy vrach 2016; 4: 78–85.
3. Society of Specialists in Heart Failure. Russian Society of Cardiology. Klinicheskie rekomendatsii. Khronicheskaya serdechnaya nedostatochnost’ (KhSN) [Clinical guidelines. Chronic heart failure (CHF)]. 2016 revision.
4. Ponikowski P., Voors A.A., Anker S.D., Bueno H., Cleland J.G.F., Coats A.J.S., Falk V., González-Juanatey J.R., Harjola V.P., Jankowska E.A., Jessup M., Linde C., Nihoyannopoulos P., Parissis J.T., Pieske B., Riley J.P., Rosano G.M.C., Ruilope L.M., Ruschitzka F., Rutten F.H., van der Meer P.; ESC Scientific Document Group. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J 2016; 37(27): 2129–2200, https://doi.org/10.1093/eurheartj/ehw128.
5. Patel A.R., Hurst J.R. Extrapulmonary comorbidities in chronic obstructive pulmonary disease: state of the art. Expert Rev Respir Med 2011; 5(5): 647–662, https://doi.org/10.1586/ers.11.62.
6. Davidovskaya E.I. Comorbidity in chronic obstructive pulmonary disease. Meditsinskaya panorama 2009; 9: 75–77.
7. Correia L.L., Lebedev T.Y., Efremova O.A., Proshchaev K.I., Litovchenko E.S. The problem of polymorbidity in cases of chronic obstructive pulmonary disease associated with some cardiovascular diseases. Nauchnye vedomosti Belgorodskogo gosudarstvennogo universiteta. Seriya: Meditsina. Farmatsiya 2013; 4(147): 12–17.
8. Gubkina V.A., Trofimov V.I., Tsvetkova L.N., Pogoda T.E., Mumortsev Y.I., Suntsov D.A. Chronic obstructive pulmonary disease and chronic heart failure in elderly people. Uchenye zapiski SPbGMU im. akad. I.P. Pavlova 2016; 23(2): 11–15.
9. Kawut S.M. COPD: cardiopulmonary disease? European Respiratory Journal 2013; 41(6): 1241–1243, https://doi.org/10.1183/09031936.00009413.
10. Aryal S., Diaz-Guzman E., Mannino D.M. Epidemiology of comorbidities in chronic obstructive pulmonary disease: clusters, phenotypes and outcomes. Italian Journal of Medicine 2012; 6(4): 276–284, https://doi.org/10.1016/j.itjm.2012.02.006.
11. Vatutin N.T., Smirnova A.S. Treatment of comorbid chronic obstructive pulmonary disease and cardiovascular disease. Pul’monologiya 2016; 26(3): 364–371.
12. Hawkins N.M., Petrie M.C., Jhund P.S., Chalmers G.W., Dunn F.G., McMurray J.J. Heart failure and chronic obstructive pulmonary disease: diagnostic pitfalls and epidemiology. Eur J Heart Fail 2009; 11(2): 130–139, https://doi.org/10.1093/eurjhf/hfn013.
13. Kang Y., Steele B.G., Burr R.L., Dougherty C.M. Mortality in advanced chronic obstructive pulmonary disease and heart failure following cardiopulmonary rehabilitation. Biol Res Nurs 2018; 20(4): 429–439, https://doi.org/10.1177/1099800418772346.
14. Chen Y.R., Chen V., Hollander Z., Leipsic J.A., Hague C.J., DeMarco M.L., FitzGerald J.M., McManus B.M., Ng R.T., Sin D.D. C-reactive protein and N-terminal prohormone brain natriuretic peptide as biomarkers in acute exacerbations of COPD leading to hospitalizations. PLoS One 2017; 12(3): e0174063, https://doi.org/10.1371/journal.pone.0174063.
15. Leshchenko I.V., Baranova I.I. Biomarkers of inflammation in chronic obstructive pulmonary disease. Pul’monologiya 2012; 2: 108–117.
16. Hawkins N.M., Khosla A., Virani S.A., McMurray J.J., FitzGerald J.M. B-type natriuretic peptides in chronic obstructive pulmonary disease: a systematic review. BMC Pulm Med 2017; 17(1): 11, https://doi.org/10.1186/s12890-016-0345-7.
17. Nazemiyeh M., Sharifi A., Amiran F., Pourafkari L., Taban Sadeghi M., Namdar H., Abbasnezhad M. Relationship between prohormone brain natriuretic peptide (NT-proBNP) level and severity of pulmonary dysfunction in patients with chronic congestive heart failure. J Cardiovasc Thorac Res 2015; 7(1): 24–27, https://doi.org/10.15171/jcvtr.2015.05.
18. Pavasini R., Tavazzi G., Biscaglia S., Guerra F., Pecoraro A., Zaraket F., Gallo F., Spitaleri G., Contoli M., Ferrari R., Campo G. Amino terminal pro brain natriuretic peptide predicts all-cause mortality in patients with chronic obstructive pulmonary disease: systematic review and meta-analysis. Chron Respir Dis 2017; 14(2): 117–126, https://doi.org/10.1177/1479972316674393.
19. Khaletskaya A.I., Kuznetsov A.N., Shcherbinina E.V., Fomin I.V. Peculiarities of comorbid course of chronic obstructive pulmonary disease and chronic cardiac insufficiency and their influence on patients’ life quality. Medicinskij al’manah 2017; 3(48): 206–210.
20. Khaletskaya A.I., Kuznetsov A.N. Assessment of life quality in the comorbid patients: chronic obstructive lung disease and chronic cardiac disease. Zdorov’e i obrazovanie v XXI veke 2017; 19(10): 98–101.
21. Morisky D.E., Green L.W., Levine D.M. Concurrent and predictive validity of a self-reported measure of medication adherence. Med Care 1986; 24; 67–74, https://doi.org/10.1097/00005650-198601000-00007.

Khaletskaya А.I., Kuznetsov А.N., Bolshova Y.V., Malysheva Т.V., Khaletskaya О.V. Cardiac Biomarkers in Patients with Isolated and Combined Course of Chronic Obstructive Pulmonary Disease and Chronic Heart Failure. Sovremennye tehnologii v medicine 2018; 10(4): 130, https://doi.org/10.17691/stm2018.10.4.15